Thomas Seufferlein
Overview
Explore the profile of Thomas Seufferlein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
331
Citations
10816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schulte L, Schulte , Beck A, Marienfeld R, Azoitei N, Barth T, et al.
J Pathol
. 2025 Feb;
265(4):401-407.
PMID: 39906959
Pancreatic ductal adenocarcinoma (PDAC) often arises from preexisting cystic lesions such as intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN). This study investigated the molecular heterogeneity and mutational...
2.
Arndt V, Doege D, Frohling S, Albers P, Algul H, Bargou R, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):39.
PMID: 39825921
No abstract available.
3.
Lahusen A, Minhofer N, Lohse K, Blechner C, Lindenmayer J, Eiseler T, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39824529
Background: Pancreatic ductal adenocarcinoma (PDAC) is mostly refractory to immunotherapy due to immunosuppression in the tumor microenvironment and cancer cell-intrinsic T cell tolerance mechanisms. PDAC is described as a "cold"...
4.
Yilmaz D, Tharehalli U, Paganoni R, Knoop P, Gruber A, Chen Y, et al.
Sci Rep
. 2025 Jan;
15(1):2180.
PMID: 39820815
Hepatocellular carcinoma (HCC) remains the most prevalent type of primary liver cancer worldwide. p53 is one of the most frequently mutated tumor-suppressor genes in HCC and its deficiency in hepatocytes...
5.
Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):37.
PMID: 39820556
Background: Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional variants of the...
6.
Ursprung S, Thaiss W, Beha J, Moller Y, Malek N, Beer M, et al.
J Pers Med
. 2024 Dec;
14(12).
PMID: 39728056
: Current guidelines recommend Cisplatin/Gemcitabine/Durvalumab as first-line treatment for inoperable or recurrent cholangiocarcinoma (CCA). Molecular tumor boards (MTB) have the expertise to support organ-specific tumor boards with evidence-based treatment recommendations...
7.
Beutel A, Ekizce M, Ettrich T, Seufferlein T, Lindenmayer J, Gout J, et al.
United European Gastroenterol J
. 2024 Nov;
13(1):21-33.
PMID: 39540683
Pancreatic ductal adenocarcinoma (PDAC) ranks among the leading causes of cancer-related deaths worldwide. Despite advances in precision oncology in other malignancies, treatment of PDAC still largely relies on conventional chemotherapy....
8.
Perkhofer L, Seufferlein T, Melzer A, Ettrich T
J Clin Oncol
. 2024 Oct;
43(3):357-359.
PMID: 39467218
No abstract available.
9.
Gaidzik V, Mayer-Steinacker R, Wittau M, Schultheiss M, V Baer A, Oehl-Huber K, et al.
Sarcoma
. 2024 Oct;
2024:5036102.
PMID: 39411551
Desmoplastic small round blue cell tumor (DSRCT) is a highly aggressive fatal sarcoma without evidence-based therapeutic guidelines. We present here seven patients with DSRCT including immunohistochemistry combined with fluorescence in...
10.
Schuhbaur J, Surovtsova I, Seufferlein T, Kokh D, Szotyori-Artz G, Winzler C, et al.
BMC Cancer
. 2024 Oct;
24(1):1280.
PMID: 39407151
Background: Ductal pancreatic adenocarcinoma (PDAC) still has a dismal prognosis even when deemed resectable. A cancer free resection margin (R0) is associated with a more favourable prognosis than the presence...